Korsana Biosciences vs Ovid Therapeutics
KRSA and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRSA and OVID compare
Ovid Therapeutics is the larger company, worth 3.1 times as much as Korsana Biosciences ($469M against $153M).
Korsana Biosciences grew revenue faster over the last twelve months (−12.6% versus −76.2% for Ovid Therapeutics).
Korsana Biosciences keeps more of each dollar of sales as profit, with a net margin of −353% compared with −2179% at Ovid Therapeutics.
Ovid Therapeutics scores higher on the StockData Score (9 against 6 for Korsana Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRSA | OVID |
|---|---|---|
| Size and price | ||
| Market cap | $153M | $469M |
| Share price | $32.68 | $2.40 |
| Change, 1 year | 224% | 100% |
| Change, 5 years | −90.5% | −26.4% |
| Beta (5Y) | 5.72 | 1.24 |
| Employees | 1 | 23 |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 80.5× (better) | 296× |
| P/B | 30.1× | 2.2× (better) |
| Fair value | $5.47 | – |
| Margin of safety | −498% | – |
| Growth | ||
| Revenue growth (TTM) | −12.6% (better) | −76.2% |
| Revenue growth, 5Y average | −2.0% (better) | −10.5% |
| Profitability | ||
| Operating margin | −359% (better) | −3687% |
| Net margin | −353% (better) | −2179% |
| Return on equity | −98.2% | −26.0% (better) |
| Return on invested capital | −116% (better) | −160% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.82 | 12.39 (better) |
| Altman Z-score | −8.97 | 10.36 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.1% | 75.3% |
| Held by insiders | – | 13.6% |
| Insider net buying, 12 months | – | −$29.3K |
| Short interest, % of float | – | 10.8% |
Go deeper
- KRSA stock overview
- KRSA income statement
- KRSA valuation and score
- OVID stock overview
- OVID income statement
- OVID valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.